Characterization of Exposure From Topical Administration of [14C] Umeclidinium to Axilla or Palm of Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

September 2, 2013

Primary Completion Date

February 19, 2014

Study Completion Date

February 19, 2014

Conditions
Hyperhidrosis
Interventions
DRUG

[14C]Umeclidinium 18.5 mg

Umeclidinium will be supplied as clear, colorless solution, free from visible particulates, single dose, topical solution in clear glass jars. Dosage of 18.5 mg of Umeclidinium per gram is equivalent to 22 mg per gram of the bromide salt.

Trial Locations (1)

9471 GP

GSK Investigational Site, Zuidlaren

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY